By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Adams Respiratory Therapeutics, Inc. et al v. Perrigo Company et al.
2:07-cv-04619; filed September 27, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,372,252 ("Guaifenesin Sustained Release Formulation and Tablets," issued April 16, 2002) following a paragraph IV certification as part of Perrigo's filing of an ANDA to manufacture a generic version of Adams' Mucinex® (guaifenesin, used to treat chest congestion). View the complaint here.
Hoffmann-La Roche Inc. v. Orchid Chemicals & Pharmaceuticals Ltd. et al.
2:07-cv-04582; filed September 25, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 7,192,938 ("Method of Treatment Using Bisphosphonic Acid," issued March 20, 2007) and 6,294,196 ("Pharmaceutical Composition Containing Diphosphonic Acid or Salt Thereof," issued September 25, 2001) following a paragraph IV certification as part of Orchid's filing of an ANDA to manufacture a generic version of Roche's Boniva® (ibandronate sodium, used to treat post-menopausal osteoporosis). View the complaint here.
Sanofi-Aventis et al. v. Actavis South Atlantic LLC et al.
1:07-cv-00572; filed September 21, 2007 in the District Court of Delaware
Sanofi-Aventis et al. v. Barr Laboratories Inc.
1:07-cv-00574; filed September 21, 2007 in the District Court of Delaware
The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 4,661,491 ("Alfuzosine Compositions and Use," issued April 28, 1987) and 6,149,940 ("Tablet with Controlled Release of Alfuzosine Chlorhydrate," issued November 21, 2000) following a paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of plaintiffs' Uroxatral® (alfuzosin hydrochloride, used to treat benign prostatic hyperplasia). View the Actavis complaint here.
Sanofi-Aventis U.S. LLC et al. v. Mayne Pharma Limited et al.
3:07-cv-04550; filed September 21, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 5,338,874 ("Cis oxalato (trans 1-1,2- cyclohexanediamine) PT(II) Having Optically High Purity," issued August 16, 1994) following a paragraph IV certification as part of Mayne's filing of an ANDA to manufacture a generic version of plaintiffs' Eloxatin® (oxaliplatin for injection, used to treat colorectal cancer). View the complaint here.
Hoffman-La Roche Inc. v. Cobalt Pharmaceuticals Inc. et al.
2:07-cv-04540; filed September 21, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 7,192,938 ("Method of Treatment Using Bisphosphonic Acid," issued March 20, 2007), 6,294,196 ("Pharmaceutical Composition Containing Diphosphonic Acid or Salt Thereof," issued September 25, 2001), and 4,927,814 ("Diphosphonate Derivatives, Pharmaceutical Compositions and Methods of Use," issued May 22, 1990) following a paragraph IV certification as part of Cobalt's filing of an ANDA to manufacture a generic version of Roche's Boniva® (150 mg once-monthly tablets) (ibandronate sodium, used to treat post-menopausal osteoporosis). View the complaint here.
Hoffman-La Roche Inc. v. Cobalt Pharmaceuticals Inc. et al.
2:07-cv-04539; filed September 21, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 6,143,326 ("Oral Pharmaceutical Preparation Containing Ibandronat," issued November 7, 2000), 6,294,196 ("Pharmaceutical Composition Containing Diphosphonic Acid or Salt Thereof," issued September 25, 2001), and 4,927,814 ("Diphosphonate Derivatives, Pharmaceutical Compositions and Methods of Use," issued May 22, 1990) following a paragraph IV certification as part of Cobalt's filing of an ANDA to manufacture a generic version of Roche's Boniva® (2.5mg tablets) (ibandronate sodium, used to treat post-menopausal osteoporosis). View the complaint here.
Hoffmann-La Roche Inc. v. Dr. Reddy's Laboratories, Ltd. et al.
2:07-cv-04516; filed September 20, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,294,196 ("Pharmaceutical Composition Containing Diphosphonic Acid or Salt Thereof," issued September 25, 2001) following a paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of Roche's Boniva® (ibandronate sodium, used to treat post-menopausal osteoporosis). View the complaint here.
Eli Lilly and Company v. Sun Pharmaceutical Industries, Limited
2:07-cv-13989; filed September 20, 2007 in the Eastern District of Michigan
Infringement of U.S. Patent No. 5,658,590 ("Treatment of Attention-Deficit/ Hyperactivity Disorder," issued August 19, 1997) following a paragraph IV certification as part of Sun's filing of an ANDA to manufacture a generic version of Lilly's Strattera® (atomoxetine hydrochloride, used to treat attention-deficit/hyperactivity disorder). View the complaint here.
Warner Chilcott Company, Inc. v. Barr Laboratories, Inc.
2:07-cv-04560; filed September 24, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,667,050 ("Chewable Oral Contraceptive," issued December 23, 2003) following a paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of Warner Chilcott's Femcon Fe® (formerly Ovcon® 35 Fe, norethindrone and ethinyl estradiol tablets, and ferrous fumarate tablets, used for oral contraception). View the complaint here.
Comments